1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Sandoz Sets Date For Spinoff

Further Details Unveiled As Novartis Issues EGM Invitation For 15 September

 
• By Dave Wallace

Novartis says its spinoff of Sandoz is set to occur “on or around 4 October” following recent board approval for the move. The company has now published a formal invitation to an EGM on 15 September, along with a shareholder information brochure and listing prospectus.

4 October circled on calendar with "save the date" note
The Sandoz spinoff is expected to happen “on or around 4 October” • Source: Shutterstock

Novartis has announced that the long-awaited spinoff of Sandoz as a standalone generics and biosimilars business is expected to take place “on or around 4 October,” as the parent company shared further details and resources ahead of an extraordinary general meeting in September.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.